EN
Patient-first cell therapy innovation
 
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.
  • 0
Jia Q., Wu W., Wang Y., Alexander P.B., Sun C., Gong Z., Cheng J., Sun H., Guan Y., Xia X., Yang L., Yi X., Wan Y., Wang H., Futreal P.A., Li Q.-J.*, Zhu B.* (2018) Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 9(1):5361. (*: Corresponding authors, PMCID: PMC6299138)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299138/


Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Products and Clinic
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer